A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function.

ABSTRACT:

Introduction

Delayed graft function (DGF) following renal transplantation is a manifestation of acute kidney injury (AKI) leading to poor long-term outcome. Current treatments have limited effectiveness in preventing DGF. Interleukin-18 (IL18), a biomarker of AKI, induces interferon-γ expression and immune activation. GSK1070806, an anti-IL18 monoclonal antibody, neutralizes activated (mature) IL18 released from damaged cells following inflammasome activation. This phase IIa, single-arm trial assessed the effect of a single dose of GSK1070806 on DGF occurrence post donation after circulatory death (DCD) kidney transplantation.

Methods

The 3 mg/kg intravenous dose was selected based on prior studies and physiologically based pharmacokinetic (PBPK) modeling, indicating the hig

SUBMITTER: Wlodek E 

PROVIDER: S-EPMC7939287 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature